Efficacy and safety of switching from lopinavir/ritonavir-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV: A multicenter retrospective study

Jiantao Fu; Yifan Guo; Guoxiang Zheng; Zongxing Yang; Jinchuan Shi; Dingyan Yan; Jianhua Yu; Lijun Sun; Hongxin Zhao

doi:10.1016/j.virs.2025.10.003

October 2025

Citation: Jiantao Fu, Yifan Guo, Guoxiang Zheng, Zongxing Yang, Jinchuan Shi, Dingyan Yan, Jianhua Yu, Lijun Sun, Hongxin Zhao. Efficacy and safety of switching from lopinavir/ritonavir-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV: A multicenter retrospective study .VIROLOGICA SINICA, 2025, 40(5) : 835-841. http://dx.doi.org/10.1016/j.virs.2025.10.003

Efficacy and safety of switching from lopinavir/ritonavir-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV: A multicenter retrospective study

Jiantao Fu ^a ,
Yifan Guo ^a ,
Guoxiang Zheng ^b ,
Zongxing Yang ^b ,
Jinchuan Shi ^b ,
Dingyan Yan ^b ,
Jianhua Yu ^{b
,,} ,
Lijun Sun ^{c
,,} ,
Hongxin Zhao ^{a
,,}

a. Clinical Center for HIV/AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China;
b. Department of Infectious Diseases, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310023, China;
c. Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100015, China

Corresponding author: Jianhua Yu, yujhmc@126.com
Lijun Sun, sunlijunkity@163.com
Hongxin Zhao, 13911022130@163.com
Received Date: 15 January 2025
Accepted Date: 14 October 2025
Available online: 20 October 2025

Abstract

In China, approximately 13% of people living with human immunodeficiency virus (HIV) (PLWH) are receiving lopinavir/ritonavir (LPV/r)-based regimens. These PLWH typically have a history of either treatment failure or intolerance to first-line efavirenz-based regimens. Given the considerable pill burden and adverse effects associated with LPV/r, treatment optimization is important for this population. This multicenter retrospective study aimed to evaluate the efficacy and safety of switching from LPV/r-based regimens to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). Virological suppression rates (HIV-RNA < 40 copies/mL) were primarily compared between the 48-week periods before and after switching to BIC/FTC/TAF. CD4 counts and metabolic data were also assessed. A total of 461 PLWH were recruited between January 2021 and December 2023, with 92.2% being male, a median age of 38 years, and a median antiretroviral therapy duration of 8 years. Prior to initiating LPV/r, 23.0% (106/461) had documented virological failure. During LPV/r treatment, 18.9% (20/106) of these individuals experienced viral rebound. Among all participants, the overall virological suppression rates significantly increased from 94.6% (pre-switch) to 98.6% (post-switch) (P < 0.001). Notably, among participants with prior virological failure, suppression rates improved significantly from 81.1% to 97.2% (P < 0.001), whereas no significant difference was observed in those without such history (from 98.6% to 99.2%, P = 0.764). The median triglyceride level decreased from 2.4 mmol/L to 1.8 mmol/L (P < 0.001), while no difference in CD4 counts was observed. These findings demonstrate that BIC/FTC/TAF is an effective and metabolically favorable treatment option for PLWH switching from LPV/r based regimens, regardless of whether they have a prior history of virological failure.
- Human immunodeficiency virus (HIV)
- , Virological suppression
- , LPV/r
- , BIC/FTC/TAF
- , Metabolic outcomes

References
1. Aboud, M., Kaplan R., Lombaard J., Zhang F., Hidalgo J.A., Mamedova E., Losso M.H., Chetchotisakd, P., Brites, C., Sievers, J., Brown, D., Hopking, J., Underwood, M., Nascimento, M.C., Punekar, Y., Gartland, M., Smith, K., 2019. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (dawning): An open-label, non-inferiority, phase 3b trial. Lancet Infect Dis, 19: 253-264.
2. Ambrosioni, J., Rojas Lievano, J., Berrocal, L., Inciarte, A., de la Mora, L., Gonzalez-Cordon, A., Martinez-Rebollar, M., Laguno, M., Torres, B., Ugarte, A., Chivite, I., Leal, L., de Lazzari, E., Miro, J.M., Blanco, J.L., Martinez, E., Mallolas, J., 2022. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother, 77: 1133-1139.
3. Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D. 2014. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed hiv (strategy-pi): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis, 14: 581-589.
4. Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. 2013. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line art regimen (second-line): A randomised, open-label, non-inferiority study. Lancet, 381: 2091-2099.
5. Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA. 2017. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with hiv with virological failure of a standard first-line antiretroviral therapy regimen: A substudy of the randomised, open-label, non-inferiority second-line study. Lancet HIV, 4: e13-e20.
6. Carr A, Samaras K, Chisholm DJ, Cooper DA. 1998. Pathogenesis of hiv-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 351: 1881-1883.
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. 1999. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet, 353: 2093-2099.
8. Chang HM, Chou PY, Chou CH, Tsai HC, 2021. Outcomes after Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Infect Drug Resist. 14: 4877-4886.
9. Croxtall JD, Perry CM. 2010. Lopinavir/ritonavir: A review of its use in the management of HIV-1 infection. Drugs, 70: 1885-1915.
10. D2EFT Study Group. 2024. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D(2)EFT): An open-label, randomised, phase 3b/4 trial. Lancet HIV, 11: e436-e448.
11. Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. 2018. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV, 5: e347-e356.
12. Damas J, Munting A, Fellay J, Haerry D, Marzolini C, Tarr PE, Steffen A, Braun DL, Stoeckle M, Bernasconi E, Nawej Tshikung O, Fux CA, Darling KEA, Beguelin C, Wandeler G, Cavassini M, Surial B. 2024. Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV. Clin Infect Dis, 79: 990-998.
13. Deeks ED. 2018. Bictegravir/emtricitabine/tenofovir alafenamide: A review in hiv-1 infection. Drugs, 78: 1817-1828.
14. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fatkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P. 2010. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (switchmrk 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet, 375: 396-407.
15. Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL. 2017. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. Aids, 31: 2503-2514.
16. Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI. 2018. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis, 18: 47-57.
17. Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. 2013. Emergence of hiv drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis, 207 Suppl 2: S49-56.
18. Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA. 2011. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS clinical trials group study A5142. AIDS, 25: 37-47.
19. Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Bethune MP, Picchio G. 2011. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the artemis study: 96-week analysis. Antivir Ther, 16: 99-108.
20. Loos NHC, Beijnen JH, Schinkel AH. 2022. The mechanism-based inactivation of CYP3A4 by ritonavir: What mechanism? Int J Mol Sci, 23: 9866.
21. Martinez-Sanz J, Serrano-Villar S, Muriel A, Garcia Fraile LJ, Orviz E, Mena de Cea A, Campins AA, Moreno S. 2023. Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): A multicenter prospective cohort study. Clin Infect Dis, 76: e652-e660.
22. Nordestgaard BG, Varbo A. 2014. Triglycerides and cardiovascular disease. Lancet, 384: 626-635.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new (Accessed 1 October 2025).
24. Park HB, Arsanjani R, Hong SJ, Yi JJ, Yi SW. 2024. Impact of hypertriglyceridaemia on cardiovascular mortality according to low-density lipoprotein cholesterol in a 15.6-million population. Eur J Prev Cardiol, 31: 280-290.
25. Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS. 2017. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: An observational analysis within the randomised, open-label, earnest trial. Lancet HIV, 4: e341-e348.
26. Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A. 2022. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of hiv infection (NADIA): Week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV, 9: e381-e393.
27. Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, Maggiolo F, Stellbrink HJ, Yazdanpanah Y, Acosta R, Huang H, Hindman JT, Martin H, Baeten JM, Wohl D. 2023. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: Five-year follow-up from two randomized trials. EClinicalMedicine, 59: 101991.
28. Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M, Holmes P, Gazzard B, Nelson M. 2007. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS, 21: 1826-1828.
29. Surial B, Mugglin C, Calmy A, Cavassini M, Gunthard HF, Stockle M, Bernasconi E, Schmid P, Tarr PE, Furrer H, Ledergerber B, Wandeler G, Rauch A. 2021. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: A cohort study. Ann Intern Med, 174: 758-767.
30. Tsai MS, Sun HY, Chen CP, Lee CH, Lee CY, Liu CE, Tang HJ, Hung TC, Li CW, Lee YT, Liou BH, Yang CJ, Hung CC. 2023. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. Int J Infect Dis, 126: 39-47.
31. van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W. 2011. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol, 83: 1764-1769.
32. Wang R, Sun L, Wang X, Zhai Y, Wang L, Ma P, Wu C, Zhou Y, Chen R, Wang R, Zhang F, Hua W, Li A, Xia W, Gao Y, Li R, Lv S, Shao Y, Cao Y, Zhang T, Wu H, Cai C, Dai L. 2024. Rapid initiation of antiretroviral therapy with coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus efavirenz, lamivudine, and tenofovir disoproxil fumarate in hiv-positive men who have sex with men in China: Week 48 results of the multicenter, randomized clinical trial. Clin Infect Dis, 79: 169-176.
33. Yuan J, Deng C, Li Q, Sun Y, Huang W, Zhang W, Liu M. 2024. Human immunodeficiency virus/acquired immune deficiency syndrome antiretroviral therapy initiated on the same day in treatment-naive people with human immunodeficiency virus: A comparative study of efficacy and regimen. Chin Med J (Engl), 137: 2720-2725.
34. Zhao Y, Han MJ, Gan XM, Ma Y, Zhao DC. 2020. Characteristics and viral suppression among people living with HIV from the national free antiretroviral therapy programme, 2019. HIV Med, 21: 701-707.
35. Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. 2014. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis, 59: 888-896.
Proportional views